Differentiated Thyroid CancerIDENTHY-KNCT05014698
IDEntification of New Predisposition Genes in Differentiated THYroid Cancer
A study testing WGS in people with Differentiated Thyroid Cancer and Thyroid Cancer, Nonmedullary, run by Nantes University Hospital at 2 sites in France.
Trial summary
The purpose of this research is to find new predisposition genes for differentiated thyroid cancer (DTC). Read more about this study
- Who is it for?
- Ages 8 years and olderHealthy volunteers can take part
- Conditions the study is for
- Differentiated Thyroid Cancer, Thyroid Cancer, Nonmedullary
- What is being tested?
- WGS
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 34 participants
- Where
- 2 sitesFrance
- Study dates
- 23 Feb 2022to 13 Jan 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 8 years and older
- All sexes
- Healthy volunteers accepted
- Child, Adult, Older adult
Who may be able to join
- Probant subjects
- Minor or adult subject
- Adult subject or legal guardian for minor subjects agreeing to sign the study consent and biospecimen consent
- Subject with differentiated thyroid cancer without an identified causative mutation in the BAP1 and DICER 1 predisposition genes
- Patient affiliated to a valid social security plan
- Relative subjects
Show all 10Show fewer
- Adult subjects
- Subject agreeing to sign the study consent and the biocollection consent
- Subject with differentiated thyroid cancer or from a family with several cases of differentiated thyroid cancer without a causal mutation identified in the BAP1 and DICER 1 predisposition genes
- Patient affiliated to a social security plan
Who cannot join
- Subject refusing to participate
- Subjects with a causal mutation identified in the predisposition genes: BAP1 and DICER 1
- Subjects under guardianship, curatorship or safeguard of justice or not socially insured
- Subjects with another syndromic predisposition to thyroid cancer (Cowden, Werner, PAF)
Trial locations and contacts
2 sites in 1 country.
France2 sites
Vendée Hospital
La Roche-sur-Yon
Nantes University Hospital
Nantes, 44093
About this study
The purpose of this research is to find new predisposition genes for differentiated thyroid cancer (DTC).
Read the detailed description
The purpose of this research is to find new predisposition genes for differentiated thyroid cancer (DTC). Therefore, in the absence of a BAP1 and DICER1 abnormality, we offer to sequence your whole genome (WGS) or partial genome (genotyping) for a previously unknown genetic abnormality.
Furthermore, the discovery of new genes would be a major medical advance that could contribute to the identification of new therapeutic targets.
This research will be conducted at the University Hospital of Nantes and the Hospital of Vendée and 95 people should participate.
- Being tested
- WGS
- Medical subject headings
- Thyroid Cancer, Papillary
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
WGSGenetic
Whole Genome sequencing
| Study group | Role | What they receive |
|---|---|---|
| WGS | Experimental | at inclusion visit :
- Blood collection for whole Genome sequencing will be performed
At final visit :
the results of the WGS will be delivered to patients Receives: Genetic: WGS |
What is being measured
The primary outcome is the main question the study is designed to answer.
Type and Number of genetic variants associated with or causing the development of differentiated thyroid cancer
To be achieved by a whole genome sequencing (WGS) approach in a familial analysis of patients with differentiated thyroid cancer. In addition, high-throughput genotyping of multiple individuals in each family will allow complementary detection of genomic regions that are shared only by affected subjects
Measured: within 2 years
Secondary outcomes (2)
Number of phenotypes associated to genotypes of CDT
By studying the association between the clinical characteristics of patients and the identified genetic variants
Measured: within 2 years
Analysis of birthplace/family origin information
Definition of the spatial location of family forms of CDT and to identify possible founding effects
Measured: within 2 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Aug 2021
- Study start23 Feb 2022
- Primary completion13 Jan 2026
- Study completion13 Jan 2026
Why it stopped: end-of-study visit not completed within the protocol timeframe
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Differentiated Thyroid CancerStudies of the same condition, open and under way.
- More trials run by Nantes University HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 34 participants (actual)
Sponsor and investigators
- Lead sponsor
- Nantes University Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05014698
- Sponsor's protocol ID
- RC19_0414
- Acronym
- IDENTHY-K
- Status last verified
- Jan 2026
- First submitted
- 5 Aug 2021
- Last updated
- 28 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 28 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- IDEntification of New Predisposition Genes in Differentiated THYroid Cancer
- ClinicalTrials.gov ID
- NCT05014698
- Acronym / sponsor ID
- IDENTHY-K / RC19_0414
- Study type
- Interventional
- Recruitment status
- TerminatedReason stopped: end-of-study visit not completed within the protocol timeframe
- Enrolment
- 34 participants (actual)
- Lead sponsor
- Nantes University HospitalUniversity, hospital or other
- Study start
- 23 Feb 2022 (actual)
- Primary completion
- 13 Jan 2026 (actual)
- Study completion
- 13 Jan 2026 (actual)
- First posted
- 20 Aug 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this research is to find new predisposition genes for differentiated thyroid cancer (DTC).
Detailed description
The purpose of this research is to find new predisposition genes for differentiated thyroid cancer (DTC). Therefore, in the absence of a BAP1 and DICER1 abnormality, we offer to sequence your whole genome (WGS) or partial genome (genotyping) for a previously unknown genetic abnormality.
Furthermore, the discovery of new genes would be a major medical advance that could contribute to the identification of new therapeutic targets.
This research will be conducted at the University Hospital of Nantes and the Hospital of Vendée and 95 people should participate.
Study design
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| WGS | Experimental | Genetic: WGSat inclusion visit : - Blood collection for whole Genome sequencing will be performed At final visit : the results of the WGS will be delivered to patients |
Who may qualify
- Ages
- 8 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (10 listed)
- Probant subjects
- Minor or adult subject
- Adult subject or legal guardian for minor subjects agreeing to sign the study consent and biospecimen consent
- Subject with differentiated thyroid cancer without an identified causative mutation in the BAP1 and DICER 1 predisposition genes
- Patient affiliated to a valid social security plan
Key exclusion criteria (4 listed)
- Subject refusing to participate
- Subjects with a causal mutation identified in the predisposition genes: BAP1 and DICER 1
- Subjects under guardianship, curatorship or safeguard of justice or not socially insured
- Subjects with another syndromic predisposition to thyroid cancer (Cowden, Werner, PAF)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| WGSWhole Genome sequencing | Genetic | WGS |
Primary outcome
Type and Number of genetic variants associated with or causing the development of differentiated thyroid cancer
Time frame: within 2 years
To be achieved by a whole genome sequencing (WGS) approach in a familial analysis of patients with differentiated thyroid cancer. In addition, high-throughput genotyping of multiple individuals in each family will allow complementary detection of genomic regions that are shared only by affected subjects
2 secondary outcomes
Number of phenotypes associated to genotypes of CDT
Time frame: within 2 years
Analysis of birthplace/family origin information
Time frame: within 2 years
Results and safety
The study was stopped early (reason given: end-of-study visit not completed within the protocol timeframe). Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Jan 2026.
- Individual participant dataSharing planned: No
Related trials for Differentiated Thyroid Cancer
RecruitingPhase 2
Study of ST-1898 in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Cancer
Differentiated Thyroid Carcinoma
Not yet recruitingObservational study
Serum Treg/Th17-Related Cytokines and Systemic Inflammatory Indices in Differentiated Thyroid Cancer
Differentiated Thyroid Cancer (DTC), Papillary Thyroid Carcinoma
RecruitingPhase 2
The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer
Thyroid Cancer
Not yet recruitingPhase 1
Study of ACC-1898 in Adult Participants With Advanced Solid Tumors
Hepatocellular Carcinoma, Renal Cell Carcinoma
Enrolling by invitationPhase 3
Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study
Cancer, Renal Cell Carcinoma (RCC)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing WGS in people with Differentiated Thyroid Cancer and Thyroid Cancer, Nonmedullary, run by Nantes University Hospital at 2 sites in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 10 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 28 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was stopped early (reason given: end-of-study visit not completed within the protocol timeframe). Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Type and Number of genetic variants associated with or causing the development of differentiated thyroid cancer (time frame: within 2 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Jan 2026.